Anavex Life Sciences Corp. (AVXL): Price and Financial Metrics


Anavex Life Sciences Corp. (AVXL): $10.87

0.82 (+8.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVXL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AVXL Stock Price Chart Interactive Chart >

Price chart for AVXL

AVXL Price/Volume Stats

Current price $10.87 52-week high $15.24
Prev. close $10.05 52-week low $7.13
Day low $10.06 Volume 1,371,869
Day high $10.89 Avg. volume 1,302,433
50-day MA $9.79 Dividend yield N/A
200-day MA $10.18 Market Cap 847.45M

Anavex Life Sciences Corp. (AVXL) Company Bio


Anavex Life Sciences Corporation is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. The company was founded in 2006 and is based in New York, New York.


AVXL Latest News Stream


Event/Time News Detail
Loading, please wait...

AVXL Latest Social Stream


Loading social stream, please wait...

View Full AVXL Social Stream

Latest AVXL News From Around the Web

Below are the latest news stories about ANAVEX LIFE SCIENCES CORP that investors may wish to consider to help them evaluate AVXL as an investment opportunity.

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | January 23, 2023

FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.

Yahoo | January 20, 2023

3 Biotech Stocks Under $15 Worth a Second Look in 2023

Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.

Yahoo | January 18, 2023

Top Picks For 2023: Anavex Life Sciences

Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett Syndrome. Let's see why it's a favorite for 2023.

TalkMarkets.com | January 6, 2023

Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why

The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.

Yahoo | December 17, 2022

Read More 'AVXL' Stories Here

AVXL Price Returns

1-mo 17.39%
3-mo -7.72%
6-mo 0.37%
1-year -16.90%
3-year 280.07%
5-year 304.09%
YTD 17.39%
2022 -46.60%
2021 221.11%
2020 108.49%
2019 66.03%
2018 -51.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.661 seconds.